Mutations Associated With Myeloid Neoplasms Risk Post-Stem Cell Transplant

Patients with TP53/PPM1D mutations in their stem cell product had an increased risk of myeloid neoplasms in patients with Hodgkin lymphoma undergoing autologous stem cell transplant.

Related Keywords

Asmita Bhatia ,School Of Medicine ,University Of Alabama At Birmingham ,Institute For Cancer Outcomes ,National Institutes Of Health ,Cancer Outcomes ,Bew White Endowed Chair ,Pediatric Oncology ,Distinguished Professor ,Vice Chair ,National Institutes ,News ,Stem Cell Transplant ,Hodgkin Lymphoma ,